Evan Schnell is a Venture Partner at Kaleida Capital, where he brings 25+ years of experience building and commercializing clinical-grade software systems across brain-computer interfaces, neuromodulation, and large-scale healthcare infrastructure. He is currently the Director of Medical Device Software at Axoft building software for clinical trials of the Fleuron™ iBCI to unlock new treatments for patients suffering from neurological disorders. He was most recently Senior Director of Software at Synchron, where he scaled the company’s software organization from Series B through Series D. At Synchron, Evan spearheaded the development of LLM-driven communication tools for nonverbal patients, creating new interfaces between neural signals and generative AI systems. He established partnerships with Apple, NVIDIA, and Amazon, helping shape emerging standards for neural data privacy and real-time brain–computer interaction.

Prior to Synchron, he was a Principal Software Engineer at Medtronic, where he contributed to the development and commercial launch of the Percept™ DBS system, including BrainSense™, the first closed-loop deep brain stimulation platform. Earlier in his career, he held senior architecture and leadership roles at McKesson and RelayHealth, scaling enterprise platforms serving tens of millions of patients. Evan holds an MBA from the University of Minnesota Carlson School of Management. At Kaleida, Evan advises on NeuroAI, BCI, and regulated digital health opportunities, with a focus on regulatory strategy, software architecture, and commercialization.